title: Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV.
abstract: During the past few years, much has been learned about pre-exposure prophylaxis (PrEP) of HIV from studies conducted in the U.S. and elsewhere. A review and summary was conducted of articles and reports published through August 2012 on the safety and efficacy of PrEP in humans; U.S.-based studies assessing PrEP knowledge, attitudes, and use among at-risk populations and healthcare providers; and models of the cost effectiveness of PrEP. PrEP is generally safe and effective and may be cost effective in a targeted population. Awareness and interest in PrEP are increasing. PrEP is an important new addition to HIV prevention services, but continued study is warranted.
authors.affiliation: Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC-Uganda, Entebbe, Uganda. jcampbel@medicine.umaryland.edu
authors.forename: James D
authors.initials: JD
authors.lastname: Campbell
authors.forename: Jeffrey H
authors.initials: JH
authors.lastname: Herbst
authors.forename: Robert T
authors.initials: RT
authors.lastname: Koppenhaver
authors.forename: Dawn K
authors.initials: DK
authors.lastname: Smith
mesh_terms: D000284:Administration, Oral; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D011322:Primary Prevention
chemical_list: D019380:Anti-HIV Agents